



What is claimed is:

- 
- 
1. A nucleic acid vector comprising a pair of adeno-associated virus 5 (AAV5) inverted terminal repeats and a promoter between the inverted terminal repeats.
 2. The vector of claim 1, wherein the promoter is an AAV promoter p5.
 3. The vector of claim 1, wherein the p5 promoter is AAV5 p5 promoter.
 4. The vector of claim 1, further comprising an exogenous nucleic acid functionally linked to the promoter.
 5. The vector of claim 1 encapsidated in an adeno-associated virus particle.
 6. The particle of claim 5, wherein the particle is an AAV5 particle.
 7. The particle of claim 5, wherein the particle is an AAV1 particle, an AAV2 particle, an AAV3 particle, an AAV4 particle or an AAV6 particle.
 8. A recombinant AAV5 virion containing a vector comprising a pair of AAV5 inverted terminal repeats.
 9. The virion of claim 8, wherein the vector further comprises an exogenous nucleic acid inserted between the inverted terminal repeats.
 10. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:1.
 11. An isolated nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NO:1.

09747789 112100

12. An isolated nucleic acid that selectively hybridizes with the nucleic acid of claim 11.
13. An isolated nucleic acid encoding an adeno-associated virus 5 Rep protein.
14. The nucleic acid of claim 13, wherein the adeno-associated virus 5 Rep protein has the amino acid sequence set forth in SEQ ID NO:2.
15. The nucleic acid of claim 13, wherein the adeno-associated virus 5 Rep protein has the amino acid sequence set forth in SEQ ID NO:3.
16. The nucleic acid of claim 13, wherein the adeno-associated virus 5 Rep protein has the amino acid sequence set forth in SEQ ID NO:12.
17. The nucleic acid of claim 13, wherein the adeno-associated virus 5 Rep protein has the amino acid sequence set forth in SEQ ID NO:14.
18. An isolated AAV 5 Rep protein. *a*
19. The isolated AAV5 Rep protein of claim 18, having the amino acid sequence set forth in SEQ ID NO:2, or a unique fragment thereof.
20. The isolated AAV5 Rep protein of claim 18, having the amino acid sequence set forth in SEQ ID NO:3, or a unique fragment thereof.
21. An isolated antibody that specifically binds the protein of claim 18.
22. An isolated AAV5 capsid protein.

09747789.112100
001211"6827260

23. The isolated AAV5 capsid protein of claim 22 having the amino acid sequence set forth in SEQ ID NO:4.
24. An isolated antibody that specifically binds the protein of claim 23.
25. The isolated AAV5 capsid protein of claim 22, having the amino acid sequence set forth in SEQ ID NO:5.
26. An isolated antibody that specifically binds the protein of claim 25.
27. The isolated AAV5 capsid protein of claim 22, having the amino acid sequence set forth in SEQ ID NO:6.
28. An isolated antibody that specifically binds the protein of claim 27.
29. An isolated nucleic acid encoding the protein of claim 22.
30. The nucleic acid of claim 29, having the nucleic acid sequence set forth in SEQ ID NO:7.
31. The nucleic acid of claim 29, having the nucleic acid sequence set forth in SEQ ID NO:8.
32. The nucleic acid of claim 29, having the nucleic acid sequence set forth in SEQ ID NO:9.
33. An isolated nucleic acid that selectively hybridizes with the nucleic acid of claim 29.

09747789.112100

- 0971789-112100
34. An AAV5 particle comprising a capsid protein consisting essentially of the amino acid sequence set forth in SEQ ID NO:6.
35. An isolated nucleic acid comprising an AAV5 p5 promoter.
36. A method of screening a cell for infectivity by AAV5, comprising contacting the cell with AAV5 and detecting the presence of AAV5 in the cells.
37. A method of determining the suitability of an AAV5 vector for administration to a subject, comprising contacting an antibody-containing sample from the subject with an antigenic fragment of a protein of claim 22 and detecting an antibody-antigen reaction in the sample, the presence of a neutralizing reaction indicating the AAV5 vector to be unsuitable for use in the subject.
38. A method of determining the presence in a subject of an AAV5-specific antibody comprising, contacting an antibody-containing sample from the subject with an antigenic fragment of the protein of claim 22 and detecting an antibody-antigen reaction in the sample, the presence of a reaction indicating the presence of an AAV5-specific antibody in the subject.
39. ^a A method of delivering a nucleic acid to a cell, comprising administering to the cell an AAV5 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.
40. The method of claim 39, wherein the AAV inverted terminal repeats are AAV5 inverted terminal repeats.
41. A method of delivering a nucleic acid to a subject comprising administering to a cell from the subject an AAV5 particle comprising the nucleic acid inserted between a

pair of AAV inverted terminal repeats, and returning the cell to the subject, thereby delivering the nucleic acid to the subject.

42. A method of delivering a nucleic acid to a cell in a subject comprising administering to the subject an AAV5 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to a cell in the subject.

43. A method of delivering a nucleic acid to a cell in a subject having antibodies to AAV2 comprising administering to the subject an AAV5 particle comprising the nucleic acid, thereby delivering the nucleic acid to a cell in the subject.

44. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:21.

45. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 23.

09717789-112100

Add a3